Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma

Clinical Cancer Research

Volumn 22, Issue 14, 2016, Pages 3593-3605

  Xu Monette, Zijun Y ^a   Deng, Qipan ^b   Manyam, Ganiraju C ^a   Tzankov, Alexander ^c   Li, Ling ^a   Xia, Yi ^a   Wang, Xiao Xiao ^a   Zou, Dehui ^a   Visco, Carlo ^d   Dybkær, Karen ^e   Li, Jun ^a   Zhang, Li ^a   Liang, Han ^a   Montes Moreno, Santiago ^f   Chiu, April ^g   Orazi, Attilio ^h   Zu, Youli ⁱ   Bhagat, Govind ^j   Richards, Kristy L ^k   Hsi, Eric D ^b   Choi, William W L ^l   Van Krieken, J Han ^m   Huh, Jooryung ⁿ   Ponzoni, Maurilio ^o   Ferreri, Andres J M ^o   Parsons, Ben M ^p   Møller, Michael B ^q   Wang, Sa A ^a   Miranda, Roberto N ^a   Piris, Miguel A ^f   Winter, Jane N ^r   Medeiros, L Jeffrey ^a   Li, Yong ^b   Young, Ken H ^a,s   more..

^a UNIVERSITY OF TEXAS   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d SAN BORTOLO HOSPITAL   (Italy)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ HOUSTON METHODIST HOSPITAL   (United States)

^j New York Presbyterian Hospital ^*  (United States)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l UNIVERSITY OF HONG KONG   (Hong Kong)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ University of Ulsan College of Medicine   (South Korea)

^o SAN RAFFAELE HOSPITAL   (Italy)

^p GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^q ODENSE UNIVERSITY HOSPITAL   (Denmark)

^r NORTHWESTERN UNIVERSITY   (United States)

^s UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; MYC PROTEIN; PROTEIN P53; R-CHOP PROTOCOL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CARCINOGENICITY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IN VIVO STUDY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; NONSENSE MUTATION; ONCOGENE MYC; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFECTS; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; MUTATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; PREDNISONE; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 84978513097     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-2296     Document Type: Article

References (50)

1. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2014;27:958-71.
2. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res 2010;107:163-224.
3. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol 2012;30:3452-9.
4. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121:4021-31; quiz 4250.
5. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121: 2253-63.
6. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012;490:116-20.
7. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012;44:1321-5.
8. Smith-Sorensen B, Hijmans EM, Beijersbergen RL, Bernards R. Functional analysis of Burkitt's lymphoma mutant c-Myc proteins. J Biol Chem 1996;271:5513-8.
9. Bhatia K, Huppi K, Spangler G, Siwarski D, Iyer R, Magrath I. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Nat Genet 1993;5: 56-61.
10. Wasylishen AR, Chan-Seng-Yue M, Bros C, Dingar D, Tu WB, Kalkat M, et al. MYC phosphorylation at novel regulatory regions suppresses transforming activity. Cancer Res 2013;73:6504-15.
11. Yano T, Sander CA, Clark HM, Dolezal MV, Jaffe ES, Raffeld M. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Oncogene 1993;8:2741-8.
12. Chakraborty AA, Scuoppo C, Dey S, Thomas LR, Lorey SL, Lowe SW, et al. A common functional consequence of tumor-derived mutations within c-MYC. Oncogene 2015;34:2406-9.
13. Hann SR. Role of post-translational modifications in regulating c-Myc proteolysis, transcriptional activity and biological function. Semin Cancer Biol 2006;16:288-302.
14. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood 2000;95:2104-10.
15. Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, et al. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011;71:925-36.
16. Pulverer BJ, Fisher C, Vousden K, Littlewood T, Evan G, Woodgett JR. Sitespecific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene 1994;9:59-70.
17. Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, et al. Evasion of the p53 tumour surveillance network by tumourderived MYC mutants. Nature 2005;436:807-11.
18. Kuttler F, Ame P, Clark H, Haughey C, Mougin C, Cahn JY, et al. c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. Oncogene 2001;20:6084-94.
19. Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep 2005;6:177-83.
20. Rabbitts TH, Forster A, Hamlyn P, Baer R. Effect of somatic mutation within translocated c-myc genes in Burkitt's lymphoma. Nature 1984; 309:592-7.
21. Taub R, Moulding C, Battey J, Murphy W, Vasicek T, Lenoir GM, et al. Activation and somatic mutation of the translocated c-myc gene in Burkitt lymphoma cells. Cell 1984;36:339-48.
22. Yu BW, Ichinose I, Bonham MA, Zajac-Kaye M. Somatic mutations in c-myc intron I cluster in discrete domains that define protein binding sequences. J Biol Chem 1993;268:19586-92.
23. Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science 1987;238:1272-5.
24. Chappell SA, LeQuesne JP, Paulin FE, deSchoolmeester ML, Stoneley M, Soutar RL, et al. A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene deregulation. Oncogene 2000;19:4437-40.
25. Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001;412:341-6.
26. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43:830-7.
27. Zhang J, Jima D, Moffitt AB, Liu Q, Czader M, Hsi ED, et al. The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 2014; 123:2988-96.
28. Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Li Y, et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012;26:2103-13.
29. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica 2013;98:255-63.
30. Xu-Monette ZY, Dabaja BS, Wang X, Tu M, Manyam GC, Tzankov A, et al. Clinical features, tumor biology and prognosis associated with MYC rearrangement and overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol 2015;28: 1555-73.
31. Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in western countries. Oncotarget 2015;6:5615-33.
32. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene 2001;20:5595-610.
33. Seitz V, Butzhammer P, Hirsch B, Hecht J, Gutgemann I, Ehlers A, et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS One 2011;6:e26837.
34. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000;97:3260-5.
35. Muthalagu N, Junttila MR, Wiese KE, Wolf E, Morton J, Bauer B, et al. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep 2014;8:1347-53.
36. Li Y, Choi PS, Casey SC, Dill DL, Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 2014;26: 262-72.
37. Schuetz JM, Johnson NA, Morin RD, Scott DW, Tan K, Ben-Nierah S, et al. BCL2 mutations in diffuse large B-cell lymphoma. Leukemia 2012;26: 1383-90.
38. Wirtenberger M, Hemminki K, Forsti A, Klaes R, Schmutzler RK, Grzybowska E, et al. c-MYC Asn11Ser is associated with increased risk for familial breast cancer. Int J Cancer 2005;117:638-42.
39. Figueiredo JC, Knight JA, Cho S, Savas S, Onay UV, Briollais L, et al. Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis. BMC Cancer 2007;7:99.
40. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002;16: 2530-43.
41. Chang DW, Claassen GF, Hann SR, Cole MD. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol 2000;20:4309-19.
42. Bueno MJ, Gomez de Cedron M, Gomez-Lopez G, Perez de Castro I, Di Lisio L, Montes-Moreno S, et al. Combinatorial effects of micro-RNAs to suppress the Myc oncogenic pathway. Blood 2011;117: 6255-66.
43. Lenz G, Nagel I, Siebert R, Roschke AV, Sanger W, Wright GW, et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007;204:633-43.
44. Robbiani DF, Bunting S, Feldhahn N, Bothmer A, Camps J, Deroubaix S, et al. AID produces DNA double-strand breaks in non-Ig genes and mature B cell lymphomas with reciprocal chromosome translocations. Mol Cell 2009;36:631-41.
45. Han L, Masani S, Yu K. Overlapping activation-induced cytidine deaminase hotspot motifs in Ig class-switch recombination. Proc Natl Acad Sci U S A 2011;108:11584-9.
46. Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell 2010;141:27-38.
47. Pelicci PG, Knowles DM2nd, Magrath I, Dalla-Favera R. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A 1986;83:2984-8.
48. Murphy W, Sarid J, Taub R, Vasicek T, Battey J, Lenoir G, et al. A translocated human c-myc oncogene is altered in a conserved coding sequence. Proc Natl Acad Sci U S A 1986;83:2939-43.
49. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2: 920-32.
50. Liu M, Duke JL, Richter DJ, Vinuesa CG, Goodnow CC, Kleinstein SH, et al. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008;451:841-5.